U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb ’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE) February 13, 2020 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news